ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Orphan Drug Designations and Orphan Subsets"
Episode Synopsis
FDA’s Orphan Drug Designation provides incentives to encourage the development of treatments for rare diseases. Listen as Mara Holinger, SVP of Regulatory Affairs at Veristat and members of the regulatory team shed light on ODD classification and the strategic use of subsets in study design.
More episodes of the podcast Advancing Revolutionary Therapies
CMC Pitfalls: From Benchtop to IND
31/10/2022
Emergency Use Authorizations
22/09/2022
Season 3 Trailer
26/08/2022
In God we trust